NEW YORK, Sept. 9-Celera Diagnostics has signed an agreement with Hyseq Pharmaceuticals and the University of California at San Francisco for access to a large collection of samples from cardiovascular patients, Hyseq announced today.
The database includes more than 12,000 DNA samples and related clinical information.
Celera will use the collection to study the genetics of cardiovascular disease.
The license is non-exclusive. Financial terms were not disclosed.
For more information, see the press release.